Mechanism-Based Inactivation of Human Cytochromes P450s: Experimental Characterization, Reactive Intermediates, and Clinical Implications

作者: Paul F. Hollenberg , Ute M. Kent , Namandjé N. Bumpus

DOI: 10.1021/TX7002504

关键词:

摘要: The P450 type cytochromes are responsible for the metabolism of a wide variety xenobiotics and endogenous compounds. Although P450-catalyzed reactions generally thought to lead detoxication xenobiotics, can also produce reactive intermediates that react with cellular macromolecules leading toxicity or P450s form them irreversible (i.e., mechanism-based) inactivation. This perspective describes fundamentals mechanism-based inactivation as it pertains enzymes. experimental approaches used characterize inactivators discussed, criteria required compound be classified inactivator outlined. kinetic scheme calculation relevant constants describe particular event presented. structural aspects important functional groups several classes molecules have been found impart upon by such acetylenes, thiol-containing compounds include isothiocyanates, thiazolidinediones, thiophenes, arylamines, quinones, furanocoumarins, cyclic tertiary amines described. Emphasis throughout this is placed on more recent findings human where site modification, whether apoprotein heme moiety, and, at least in part, identity intermediate loss activity known inferred. Recent advances trapping procedures well new methods identification A clinically drugs act discussed. these has potential causing serious drug-drug interactions may severe toxicological effects. clinical significance inactivating improving drug efficacy safety discussed along exploiting therapeutic benefits.

参考文章(134)
Yasuhiro Masubuchi, Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metabolism and Pharmacokinetics. ,vol. 21, pp. 347- 356 ,(2006) , 10.2133/DMPK.21.347
Hsia-lien Lin, Ute M. Kent, Paul F. Hollenberg, Mechanism-Based Inactivation of Cytochrome P450 3A4 by 17α-Ethynylestradiol: Evidence for Heme Destruction and Covalent Binding to Protein Journal of Pharmacology and Experimental Therapeutics. ,vol. 301, pp. 160- 167 ,(2002) , 10.1124/JPET.301.1.160
Franca M Buratti, Maria Teresa Volpe, Annarita Meneguz, Luciano Vittozzi, Emanuela Testai, CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. Toxicology and Applied Pharmacology. ,vol. 186, pp. 143- 154 ,(2003) , 10.1016/S0041-008X(02)00027-3
Michael Murray, Alison M. Butler, Biotransformation of Parathion in Human Liver: Participation of CYP3A4 and its Inactivation during Microsomal Parathion Oxidation Journal of Pharmacology and Experimental Therapeutics. ,vol. 280, pp. 966- 973 ,(1997)
Linda B. von Weymarn, Jamie A. Chun, Paul F. Hollenberg, Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers Carcinogenesis. ,vol. 27, pp. 782- 790 ,(2006) , 10.1093/CARCIN/BGI301
Mats Hidestrand, Magnus Ingelman-Sundberg, Miia Turpeinen, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Mikael Oscarson, CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes Drug Metabolism and Disposition. ,vol. 29, pp. 1480- 1484 ,(2001)
E. Fontana, P. Dansette, S. Poli, Cytochrome P450 enzymes mechanism based inhibitors: Common sub-structures and reactivity Current Drug Metabolism. ,vol. 6, pp. 413- 454 ,(2005) , 10.2174/138920005774330639
Eric F. Johnson, C. David Stout, Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases Biochemical and Biophysical Research Communications. ,vol. 338, pp. 331- 336 ,(2005) , 10.1016/J.BBRC.2005.08.190
Deepak Dalvie, Evan Smith, Alan Deese, Stephen Bowlin, IN VITRO METABOLIC ACTIVATION OF THIABENDAZOLE VIA 5-HYDROXYTHIABENDAZOLE: IDENTIFICATION OF A GLUTATHIONE CONJUGATE OF 5-HYDROXYTHIABENDAZOLE Drug Metabolism and Disposition. ,vol. 34, pp. 709- 717 ,(2006) , 10.1124/DMD.105.008094